ALTEROME Trademark

Trademark Overview

On Thursday, May 5, 2022, a trademark application was filed for ALTEROME with the United States Patent and Trademark Office. The USPTO has given the ALTEROME trademark a serial number of 97397313. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Thursday, September 19, 2024. This trademark is owned by Alterome Therapeutics, Inc.. The ALTEROME trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical drug development services; Pharmaceutical products development
alterome

General Information

Serial Number97397313
Word MarkALTEROME
Filing DateThursday, May 5, 2022
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateThursday, September 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 4, 2023

Trademark Statements

Goods and ServicesPharmaceutical drug development services; Pharmaceutical products development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 10, 2022
Primary Code042
First Use Anywhere DateWednesday, May 1, 2024
First Use In Commerce DateWednesday, May 1, 2024

Trademark Owner History

Party NameAlterome Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92128
Party NameAlterome Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92128

Trademark Events

Event DateEvent Description
Monday, May 9, 2022NEW APPLICATION ENTERED
Tuesday, May 10, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 23, 2023ASSIGNED TO EXAMINER
Wednesday, March 1, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 28, 2023SOU EXTENSION 1 FILED
Tuesday, November 28, 2023SOU EXTENSION 1 GRANTED
Wednesday, November 29, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 4, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 28, 2024TEAS STATEMENT OF USE RECEIVED
Friday, May 31, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, May 31, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, May 31, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, July 6, 2024USE AMENDMENT FILED
Saturday, July 6, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, June 4, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 4, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, July 6, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 19, 2024NON-FINAL ACTION E-MAILED
Thursday, September 19, 2024SU - NON-FINAL ACTION - WRITTEN
Thursday, September 19, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

alterome pharmaceutical development products services drug